Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Bronstein, Gewirtz & Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros’ announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for a triplet regimen in acute myeloid leukemia (AML) patients. This decision was based on a prespecified interim analysis indicating a low probability of success in demonstrating superiority at the final analysis.
Investors who purchased Syros securities are encouraged to participate in the investigation. The law firm is offering its services on a contingency fee basis, meaning fees will only be charged if the case is successful. Bronstein, Gewirtz & Grossman, has a track record of recovering significant sums for investors in securities fraud class actions and shareholder derivative suits.
Bronstein, Gewirtz & Grossman sta indagando su potenziali richieste contro Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). L’indagine segue l’annuncio di Syros del 12 agosto 2024, che ha comunicato che interromperà l’arruolamento nello studio clinico di Fase 2 SELECT-AML-1 per un regime triplo in pazienti con leucemia mieloide acuta (LMA). Questa decisione è stata presa sulla base di un’analisi intermedia predefinita che indicava una bassa probabilità di successo nel dimostrare la superiorità nell’analisi finale.
Si invita gli investitori che hanno acquistato titoli Syros a partecipare all’indagine. Lo studio legale offre i propri servizi con una base di pagamento di tipo contingente, il che significa che le spese saranno addebitate solo se il caso avrà successo. Bronstein, Gewirtz & Grossman ha una storia di recupero di somme significative per gli investitori in azioni collettive per frode sui titoli e cause derivate dai soci.
Bronstein, Gewirtz & Grossman está investigando posibles reclamaciones contra Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). La investigación sigue el anuncio de Syros del 12 de agosto de 2024, en el que declaró que interrumpirá la inscripción en el ensayo clínico de Fase 2 SELECT-AML-1 para un régimen triple en pacientes con leucemia mieloide aguda (LMA). Esta decisión se basó en un análisis intermedio predefinido que indicaba una baja probabilidad de éxito en demostrar superioridad en el análisis final.
Se alienta a los inversionistas que compraron valores de Syros a participar en la investigación. El bufete de abogados ofrece sus servicios con una base de honorarios contingentes, lo que significa que solo se cobrarán honorarios si el caso es exitoso. Bronstein, Gewirtz & Grossman tiene un historial de recuperar sumas significativas para los inversionistas en acciones colectivas por fraude en valores y demandas derivadas de accionistas.
Bronstein, Gewirtz & Grossman은 Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)에 대한 잠재적 청구를 조사하고 있습니다. 이 조사는 Syros가 2024년 8월 12일에 SELECT-AML-1 2상 임상 시험의 등록을 중단할 것이라고 발표한 후 진행되었습니다. 이 결정은 최종 분석에서 우월성을 입증할 낮은 성공 확률을 나타내는 사전 지정된 중간 분석에 기반하였습니다.
Syros의 증권을 구매한 투자자들은 조사에 참여할 것을 권장합니다. 이 법무법인은 성과 보수제로 서비스를 제공하며, 이는 사건이 성공할 경우에만 수수료가 부과됨을 의미합니다. Bronstein, Gewirtz & Grossman은 증권 사기 집단 소송 및 주주 파생 소송에서 투자자에게 상당한 금액을 회수한 경력이 있습니다.
Bronstein, Gewirtz & Grossman enquête sur d’éventuelles réclamations contre Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). L’enquête fait suite à l’annonce de Syros le 12 août 2024, selon laquelle la société cessera l’inscription à l’essai clinique de phase 2 SELECT-AML-1 pour un régime triple chez les patients atteints de leucémie myéloïde aiguë (LMA). Cette décision était fondée sur une analyse intermédiaire prédéfinie indiquant une faible probabilité de succès dans la démonstration de la supériorité lors de l’analyse finale.
Les investisseurs ayant acheté des titres de Syros sont encouragés à participer à l’enquête. Le cabinet d’avocats propose ses services sur une base de frais conditionnels, ce qui signifie que des frais ne seront facturés que si l’affaire est couronnée de succès. Bronstein, Gewirtz & Grossman a un palmarès en matière de récupération de sommes importantes pour les investisseurs dans des actions collectives de fraude sur titres et des poursuites dérivées des actionnaires.
Bronstein, Gewirtz & Grossman untersucht mögliche Ansprüche gegen Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). Die Untersuchung folgt auf die Bekanntgabe von Syros am 12. August 2024, dass es die Rekrutierung einstellen wird für die SELECT-AML-1 Phase-2-Klinische Studie für ein dreifaches Regime bei Patienten mit akuter myeloischer Leukämie (AML). Diese Entscheidung basierte auf einer vorher festgelegten Zwischenanalyse, die eine geringe Erfolgswahrscheinlichkeit für die Demonstration der Überlegenheit bei der Abschlussanalyse anzeigte.
Investoren, die Wertpapiere von Syros erworben haben, werden ermutigt, an der Untersuchung teilzunehmen. Die Kanzlei bietet ihre Dienste auf Erfolgsbasis an, was bedeutet, dass Gebühren nur im Erfolgsfall des Falls erhoben werden. Bronstein, Gewirtz & Grossman hat eine nachweisliche Erfolgsbilanz bei der Rückgewinnung erheblicher Summen für Investoren in Sammelklagen wegen Wertpapierbetrugs und abgeleiteten Klagen von Aktionären.
Negative
- Discontinuation of enrollment in SELECT-AML-1 Phase 2 clinical trial
- Low probability of success for the triplet regimen in AML treatment
- Potential legal claims against the company
- Possible negative impact on investor confidence and stock value
The investigation into Syros Pharmaceuticals raises significant legal and financial concerns for investors. The discontinuation of the SELECT-AML-1 Phase 2 clinical trial is a major setback that could potentially lead to securities fraud claims. Investors who purchased SYRS securities during the relevant period may have grounds for legal action if it’s found that the company withheld material information or made misleading statements about the trial’s prospects.
The key issue here is whether Syros had prior knowledge of the trial’s low probability of success but failed to disclose this information promptly. If evidence suggests that the company delayed releasing this negative news, it could constitute a violation of securities laws. Shareholders should closely monitor the investigation’s progress and consider their legal options, including potential participation in a class action lawsuit to recover losses.
The discontinuation of the SELECT-AML-1 Phase 2 trial is a significant blow to Syros’s pipeline. The triplet regimen of tamibarotene with venetoclax and azacitidine was a promising approach for AML patients with RARA gene overexpression. The decision to halt enrollment based on a prespecified interim analysis suggests that the efficacy data was underwhelming.
This outcome raises questions about the company’s drug development strategy and the validity of their approach to targeting gene overexpression in AML. It may force Syros to reevaluate its entire clinical program and could have ripple effects on other ongoing trials. Investors should be wary of the company’s ability to deliver on its remaining pipeline assets and consider the potential for further setbacks in other clinical programs.
The news of the trial discontinuation is likely to have a substantial negative impact on Syros’s stock price and financial outlook. Clinical-stage biotech companies like Syros rely heavily on positive trial results to maintain investor confidence and secure future funding. This setback could lead to:
- A significant drop in market capitalization
- Increased difficulty in raising capital for future R&D
- Potential restructuring or cost-cutting measures
Investors should reassess Syros’s cash runway and burn rate in light of this development. The company may need to pivot its strategy, potentially focusing on other pipeline candidates or seeking strategic alternatives. This event underscores the high-risk nature of biotech investments and the importance of maintaining a diversified portfolio in this sector.
NEW YORK CITY, NY / ACCESSWIRE / August 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. (“Syros” or “the Company”) (NASDAQ:SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SYRS.
Investigation Details
On August 12, 2024, Syros issued a press release “announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.” According to the Company, the “decision is based on the results of a prespecified interim analysis of the trial,” and its analysis that “the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low.”
What’s Next?
If you are aware of any facts relating to this investigation or purchased Syros securities, you can assist this investigation by visiting the firm’s site: bgandg.com/SYRS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz and Grossman, LLC
View the original press release on accesswire.com
FAQ
What is the reason for the investigation into Syros Pharmaceuticals (SYRS)?
The investigation is due to Syros Pharmaceuticals’ announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for a triplet regimen in acute myeloid leukemia (AML) patients, based on a low probability of success.
What was the outcome of the SELECT-AML-1 Phase 2 clinical trial for Syros Pharmaceuticals (SYRS)?
The SELECT-AML-1 Phase 2 clinical trial was discontinued due to a prespecified interim analysis indicating a low probability of demonstrating superiority at the final analysis for the triplet regimen in AML treatment.
How can investors participate in the investigation of Syros Pharmaceuticals (SYRS)?
Investors who purchased Syros Pharmaceuticals securities can assist in the investigation by visiting the firm’s website at bgandg.com/SYRS or contacting Peretz Bronstein or Nathan Miller of Bronstein, Gewirtz & Grossman, at 332-239-2660.
What are the potential consequences for Syros Pharmaceuticals (SYRS) following this investigation?
The investigation may lead to potential legal claims against Syros Pharmaceuticals, which could result in financial liabilities and damage to the company’s reputation. This may also negatively impact investor confidence and the stock value of SYRS.
